¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal reacting dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • dose rate meter
    ¼±·®·ü°è, ¼±·®·üÃøÁ¤±â
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • effective dose
    1. À¯È¿¿ë·® 2. À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • erythema dose
    È«¹Ý¼±·®
  • fatal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • fractional dose
    1. ºÐÇÒ¿ë·® 2. ºÐÇÒ¼±·®
  • high dose rate
    °í¼±·®·ü
  • high dose rate intraluminal radiotherapy
    °í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose profile
    ¹æ»ç¼±·®Ãø¸éµµ
  • dose rate
    ¼±·®·ü
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
  • dose rate variation
    ¼±·®·üº¯ÀÌ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • priming dose
    ÃÊȸÇ׿øÀڱط®.(¾à¸®)ÃÊȸ(¿ë)·®.
  • priming dose
    ÃÊȸÇ׿øÀڱط®.[¾à¸®]ÃÊȸ(¿ë)·®, ºÎÇÏ(¿ë)·®.
  • quasithreshold dose, Dq
    ÁØÇѰ輱·®
  • radiation absorbed dose
    ¹æ»ç¼±Èí¼ö¼±·®
  • radiation dose (rad)
    ¹æ»ç¼±·®
  • reference dose
    ±âÁؼ±·®
  • relative dose
    ºñ±³ Á¶»ç·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • minimal identifiable odor
    ÃÖ¼ÒºÐÇØÃë°¢
  • minimal nerve excitability test =NET
    ÃּҽŰæÀڱذ˻ç
  • minimal separable acuity
    ÃÖÀúºÐÇØ´É.
  • minimal stimulating test
    ¹Ì¾àÁÖÀÔÀڱعý(Ú°å°ñ¼ìýô§Ð½Ûö).
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø(õÌá³ô§Ð½).
  • minimal temperature
    ÃÖÀú¿Âµµ.
  • minimal visible acuity
    Ãּҽ÷Â(¡­ãÊæ³).
  • minimal visible angle
    Ãּҽð¢(¡­ãÊÊÇ).
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable dose
    ¿ëÀμ±·®, ¼ö¿ë¼±·®, Çã¿ë¼±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MIH Master of Industrial Health; migraine with interval headache; minimal intermittent heparin [dose]
SRS-A Slow Reacting Substance of Anaphylaxis
BPRS brief psychiatric rating scale; brief psychiatric reacting scale
CRC cardiovascular reflex conditioning; clinical research center; colorectal carcinoma; concentrated red...
CRF case report form; chronic renal failure; chronic respiratory failure; coagulase-reacting factor; con...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MEM Minimal Essential Medium
MIC Minimal Inhibition Concentration
MIC Minimal Inhibitory Concentration
MIC90 Minimal Inhibitory Concentration
MRD Minimal Residual Disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • loading dose
    ºÎÇÏ ¿ë·®, ºÎÇÏ·®
  • maintenance dose
    À¯Áö·®, À¯Áö ¿ë·®
    ÀÏÁ¤ÇÑ »óŸ¦ À¯ÁöÇϱâ À§Çؼ­ ÇÊ¿äÇÑ ¾àÁ¦ÀÇ Åõ¿©·®.
  • maximal dose
    ÃÖ´ë ¿ë·®
  • maximum accumulation dose
    ÃÖ´ë ÃàÀû·®
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • mean effective dose
    50% À¯È¿·®
  • mean lethal dose
    50% Ä¡»ç·®
  • mean target dose
    Æò±Õ Ç¥Àû ¼±·®
  • metered-dose inhaler

    methacholine (¸ÞŸÄݸ°

    °­·ÂÇÑ Äݸ° ÀÛµ¿Á¦·Î¼­ ¾Æ¼¼Æ¿Äݸ°°ú °°Àº ÀÛ¿ëÀÌ ÀÖ´Ù.
  • midbreast dose
    À¯¹æ Áß¾Ó Á¶»ç¼±·®
  • minimum dose
    ÃÖ¼Ò·®
  • minimum hemolytic dose
    ÃÖ¼Ò ¿ëÇ÷·®
  • minimum inhibitory dose
    ÃÖ¼Ò ¾ïÁ¦·®
  • optimal dose
    ÃÖÀû·®, ÀûÁ¤·®
  • oral dose
    ±¸°­ ¿ë·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
dose-effect curve This is a graph drawn to show the relationship between the dose of a drug or other chemical and the magnitude of the graded effect that it produces.
(09 Oct 1997)
dose-escalation A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose fractionation Adminstration of the total dose of radiation (radiation dosage) in parts, at timed intervals.
(12 Dec 1998)
dose intensity In chemotherapy, the total amount of drug delivered in a one-week period. Can be given all at once or over a period of several days.
(16 Dec 1997)
dose-ranging A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose-response curve This is a graph to show the relation between the dose of a drug or other chemical and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(09 Oct 1997)
dose-response relationship Relationship in which a change in the amount, intensity, or duration of exposure is associated with a change in risk of a specified outcome.
(05 Mar 2000)
dose-response relationship, drug The relationship between the dose of an administered drug and the response of the organism to the drug.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
initial dose A comparatively large dose given at the beginning of treatment to get the patient under the influence of the drug.
Synonym: loading dose.
(05 Mar 2000)
integral dose The total energy absorbed by the body, the product of the mass of tissue irradiated and the absorbed dose; unit, the gram rad.
(05 Mar 2000)
optimum dose The dose of a drug or radiation that will produce the desired effect with minimum likelihood of undesirable symptoms.
(05 Mar 2000)
therapeutic dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á